KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)

Historic Change in Receivables for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q1 2025 value amounting to -$25.0 million.

  • CRISPR Therapeutics AG's Change in Receivables rose 8750.0% to -$25.0 million in Q1 2025 from the same period last year, while for Dec 2025 it was -$25.0 million, marking a year-over-year increase of 8571.43%. This contributed to the annual value of -$25.0 million for FY2025, which is 8571.43% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Change in Receivables of -$25.0 million as of Q1 2025, which was up 8750.0% from $25.0 million recorded in Q4 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Change in Receivables peaked at $200.0 million during Q4 2023, and registered a low of -$200.0 million during Q1 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's median Change in Receivables value was -$17000.0 (recorded in 2022), while the average stood at -$11076.9.
  • Over the last 5 years, CRISPR Therapeutics AG's Change in Receivables had its largest YoY gain of 40826326.53% in 2023, and its largest YoY loss of 41166470.59% in 2023.
  • CRISPR Therapeutics AG's Change in Receivables (Quarter) stood at $153000.0 in 2021, then tumbled by 132.03% to -$49000.0 in 2022, then soared by 408263.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024, then tumbled by 200.0% to -$25.0 million in 2025.
  • Its last three reported values are -$25.0 million in Q1 2025, $25.0 million for Q4 2024, and -$200.0 million during Q1 2024.